132 related articles for article (PubMed ID: 37775434)
1. Use of molecular testing results to analyze the overuse of atypia of undetermined significance in thyroid cytology.
Martinez Coconubo D; Levy JJ; Kerr DA; Vaickus LJ; Vidis L; Glass RE; Gutmann EJ; Marotti JD; Liu X
J Am Soc Cytopathol; 2023; 12(6):451-460. PubMed ID: 37775434
[TBL] [Abstract][Full Text] [Related]
2. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
[TBL] [Abstract][Full Text] [Related]
3. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
4. Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations: Follow-Up and Outcome Experience in Newfoundland, Canada.
Erivwo P; Ghosh C
Acta Cytol; 2018; 62(2):85-92. PubMed ID: 29486467
[TBL] [Abstract][Full Text] [Related]
5. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
[TBL] [Abstract][Full Text] [Related]
6. Outcome of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid fine-needle aspirations: A six-year institutional experience.
Xu XM; Angelova E; Clement CG
Diagn Cytopathol; 2021 Aug; 49(8):915-920. PubMed ID: 33973739
[TBL] [Abstract][Full Text] [Related]
7. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
8. Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.
Babajani A; Rahmani S; Raoufi M; Eidgahi ES; Dastjerdi AV; Behfarnia P; Khalili S; Moghaddam NA
Front Endocrinol (Lausanne); 2023; 14():1135196. PubMed ID: 37313444
[TBL] [Abstract][Full Text] [Related]
9. The risk of malignancy in the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category subgroups: a Thai institute experience.
Jiragawasan C; Himakhun W
J Am Soc Cytopathol; 2024; 13(1):16-22. PubMed ID: 37903698
[TBL] [Abstract][Full Text] [Related]
10. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
11. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
12. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
[TBL] [Abstract][Full Text] [Related]
13. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
14. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
[TBL] [Abstract][Full Text] [Related]
15. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
16. Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance.
Onken AM; VanderLaan PA; Hennessey JV; Hartzband P; Nishino M
Cancer Cytopathol; 2021 Dec; 129(12):947-955. PubMed ID: 34314102
[TBL] [Abstract][Full Text] [Related]
17. Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules.
Jin X; Lew M; Pantanowitz L; Smola B; Jing X
Cancer Cytopathol; 2022 Nov; 130(11):891-898. PubMed ID: 35789120
[TBL] [Abstract][Full Text] [Related]
18. Atypia of undetermined significance in thyroid cytology: Nuclear atypia and architectural atypia are associated with different molecular alterations and risks of malignancy.
Glass RE; Levy JJ; Motanagh SA; Vaickus LJ; Liu X
Cancer Cytopathol; 2021 Dec; 129(12):966-972. PubMed ID: 34399035
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
20. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
